Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 12/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17806302 | 0.85 | RET (0.42) | LRRK2USP30RET | |
| SCHEMBL17809771 | 0.80 | BRD4 (0.39) | LRRK2RETBRD4CREBBP | |
| SCHEMBL17809538 | 0.80 | ERN1 (0.47) | LRRK2USP30BRD4CREBBP | |
| SCHEMBL17809747 | 0.77 | USP30 (0.50) | LRRK2USP30RETCREBBPCNR1 | |
| SCHEMBL17809646 | 0.77 | USP30 (0.58) | LRRK2USP30RETCREBBPCNR1 | |
| SCHEMBL17794569 | 0.77 | USP30 (0.53) | LRRK2USP30RETBRD4CREBBP | |
| SCHEMBL15559964 | 0.74 | LRRK2 (0.38) | LRRK2USP30RETCNR1CNR2 | |
| SCHEMBL17809629 | 0.72 | USP30 (0.53) | LRRK2USP30BRD4CREBBP | |
| SCHEMBL17809509 | 0.71 | WDR5 (0.56) | LRRK2BRD4CREBBPPIK3CD | |
| SCHEMBL17809508 | 0.71 | KDM1A (0.49) | BRD4CREBBPPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | LRRK2 1250/4885USP30 2156/4885RET 855/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | LRRK2 1250/4885USP30 2156/4885RET 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.